Pdt Partners, LLC Crinetics Pharmaceuticals, Inc. Transaction History

Pdt Partners, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$16.49 - $27.64 $165,411 - $277,256	-10,031 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$17.15 - $28.31 $172,031 - $283,977	10,031 New	10,031 $220,000
Q3 2021 Nov 15, 2021	SELL	$16.88 - $25.23 $192,600 - $287,874	-11,410 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$15.9 - $21.15 $49,751 - $66,178	-3,129 Reduced 21.52%	11,410 $215,000
Q1 2021 May 17, 2021	SELL	$13.3 - $17.55 $163,058 - $215,163	-12,260 Reduced 45.75%	14,539 $222,000

Q4 2020 Feb 16, 2021	BUY	$12.08 - $17.46 $42,980 - $62,122	3,558 Added 15.31%	26,799 $378,000
Q3 2020 Nov 16, 2020	BUY	$13.62 - $17.66 $316,542 - $410,436	23,241 New	23,241 $364,000

220

75.8M

631K

749K

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.41B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.